stockrow
Saturday 7 November 2026
Export ATXI’s income statement to Excel — free account
Avenue Therapeutics, Inc.
ATXI Healthcare Biotechnology
Avenue Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million.
- EPS
- −290.9%
- Free cash flow
- −169.9%
Quarter to June 2026, against a year earlier
0.43
0.03
+7.50%
Follow ATXI
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 1 | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | 100.00 | — | — | ||||||
| EBT | (3) | (12) | (22) | (26) | (5) | (4) | (4) | (10) | (12) | (3) | (3) | (0.8%) | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (209.90) | 0.00 | (209.9) pt | ||||||
| Net income | (3) | (12) | (22) | (26) | (5) | (4) | (4) | (10) | (12) | (3) | (3) | (0.8%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.45 | 0.00 | n/m | |||||
| Earnings | (1,251.76) | (2,085.42) | (2,367.24) | (1,859.97) | (349.45) | (248.00) | (122.56) | (73.68) | (15.79) | (0.93) | (0.85) | (55.1%) | ||||||
| Cash flow | (652.80) | (1,152.88) | (2,001.76) | (1,889.14) | (315.96) | (248.34) | (261.03) | (67.03) | (6.97) | (0.59) | (0.42) | (54.1%) | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (652.80) | (1,152.88) | (2,001.76) | (1,889.14) | (315.96) | (248.34) | (261.03) | (67.03) | (6.97) | (0.59) | (0.42) | (54.1%) | ||||||
| Book value | (3,299.20) | 3,284.75 | (69.34) | 489.21 | 161.58 | 228.54 | 112.23 | 4.64 | 1.43 | 0.59 | 0.17 | n/m | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 3 | +120.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | 1.16 | 2.49 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | 0.18 | 0.09 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (2) | (7) | (18) | (26) | (5) | (4) | (8) | (9) | (9) | (2) | (1) | +1.3% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | (2) | (7) | (18) | (26) | (5) | (4) | (8) | (9) | (9) | (2) | (1) | +1.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | (6) | 19 | (1) | 7 | 2 | 3 | 3 | 1 | 2 | 2 | 1 | n/m | |||||
| Net debt | 2 | (22) | (3) | (9) | (3) | (4) | (7) | (2) | (3) | (3) | (2) | n/m | ||||||
| Shareholders’ equity | (8) | 19 | (1) | 7 | 2 | 3 | 3 | 1 | 2 | 2 | 1 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (3,011.37) | (109.61) | (161.44) | (385.54) | (84.72) | (103.57) | (65.75) | (238.69) | (905.00) | (103.84) | (90.50) | +2,907.5 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | 47.48 | (220.23) | (229.86) | (839.94) | (112.48) | (128.43) | (105.76) | (529.44) | (1,630.44) | (157.75) | (163.30) | (205.2) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 3 | 2 | 6 | 4 | 4 | 4 | 2 | 3 | 2 | 1 | — | (11.5%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.40 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2025 · fundamentals updated 26 Oct 2026
Avenue Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MTNB Matinas Biopharma Holdings, Inc. | $1.1M | — (loss-making) | — (loss-making) | 0.00% | n/m | +9.15% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BBLG Bone Biologics Corp. | $1.1M | — (loss-making) | — | — | n/m | +9.99% (above 0%: growing) | — | 0.00% | Compare |
| VBIO Valion Bio, Inc. | $1.1M | — (loss-making) | — (loss-making) | +15.87% (above 0%: growing) | n/m | −189.01% (below 0%: shrinking) | (99.32%) | 0.00% | Compare |
| BPTH Bio-Path Holdings, Inc. | $1.1M | — (loss-making) | — (loss-making) | — | n/m | +98.68% (above 0%: growing) | 0.00% | 0.00% | Compare |
| JAGX Jaguar Animal Health, Inc. | $950.0K | — (loss-making) | — (loss-making) | −58.88% (below 0%: shrinking) | n/m | +13.83% (above 0%: growing) | 15.84% | (620.16%) | Compare |
| SPRC SciSparc Ltd. | $880.0K | — (loss-making) | 7.9× | — | n/m | +14.95% (above 0%: growing) | 35.75% | 0.00% | Compare |
| LNAI Lunai Bioworks Inc. | $830.0K | — (loss-making) | — | — | n/m | −1.65% (below 0%: shrinking) | 100.00% | (6,877.49%) | Compare |
| ATXI Avenue Therapeutics, Inc. | $680.0K | — (loss-making) | — (loss-making) | — | n/m | −169.89% (below 0%: shrinking) | 100.00% | 0.00% | |
| MLEC Moolec Science SA | $620.0K | — (loss-making) | — (loss-making) | +948.39% (above 0%: growing) | n/m | +4.48% (above 0%: growing) | (25.52%) | (77.92%) | Compare |
| Median of peers | $1.0M | — | — | +7.94% | — | +9.57% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 5 December 2025
Ownership
Directors and executive officers, together
8.60%
Fortress Biotech, Inc.
10.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement